Kaveri Pohlman
Stock Analyst at Clear Street
(0.60)
# 4,042
Out of 5,067 analysts
29
Total ratings
25%
Success rate
-16.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kaveri Pohlman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TRVI Trevi Therapeutics | Maintains: Buy | $11 → $21 | $11.41 | +84.05% | 1 | Nov 14, 2025 | |
| ZURA Zura Bio | Initiates: Buy | $18 | $3.74 | +381.28% | 1 | Nov 13, 2025 | |
| SGMT Sagimet Biosciences | Initiates: Buy | $29 | $6.67 | +334.78% | 1 | Oct 22, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Buy | $41 → $60 | $29.12 | +106.04% | 2 | Oct 21, 2025 | |
| VTYX Ventyx Biosciences | Initiates: Buy | $11 | $9.95 | +10.55% | 1 | Oct 1, 2025 | |
| ORKA Oruka Therapeutics | Maintains: Buy | $46 | $29.87 | +54.00% | 1 | Sep 17, 2025 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $32 | $21.51 | +48.77% | 1 | Jun 25, 2025 | |
| MGNX MacroGenics | Downgrades: Neutral | n/a | $1.42 | - | 4 | Aug 1, 2024 | |
| GMAB Genmab | Maintains: Buy | $46 → $47 | $30.82 | +52.50% | 3 | Jun 27, 2024 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $20 → $30 | $12.93 | +132.02% | 2 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $56 → $38 | $16.74 | +127.00% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $5 | $7.41 | -32.52% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $62 | $31.53 | +96.64% | 1 | Mar 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $5.15 | +55.34% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $42.25 | -36.09% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $70 | $23.18 | +201.98% | 1 | Aug 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $2.06 | +482.52% | 1 | Aug 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $8 | $3.97 | +101.51% | 2 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12,320 → $4,928 | $4.85 | +101,508.25% | 2 | Feb 9, 2022 |
Trevi Therapeutics
Nov 14, 2025
Maintains: Buy
Price Target: $11 → $21
Current: $11.41
Upside: +84.05%
Zura Bio
Nov 13, 2025
Initiates: Buy
Price Target: $18
Current: $3.74
Upside: +381.28%
Sagimet Biosciences
Oct 22, 2025
Initiates: Buy
Price Target: $29
Current: $6.67
Upside: +334.78%
RAPT Therapeutics
Oct 21, 2025
Maintains: Buy
Price Target: $41 → $60
Current: $29.12
Upside: +106.04%
Ventyx Biosciences
Oct 1, 2025
Initiates: Buy
Price Target: $11
Current: $9.95
Upside: +10.55%
Oruka Therapeutics
Sep 17, 2025
Maintains: Buy
Price Target: $46
Current: $29.87
Upside: +54.00%
ArriVent BioPharma
Jun 25, 2025
Initiates: Buy
Price Target: $32
Current: $21.51
Upside: +48.77%
MacroGenics
Aug 1, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.42
Upside: -
Genmab
Jun 27, 2024
Maintains: Buy
Price Target: $46 → $47
Current: $30.82
Upside: +52.50%
Cullinan Therapeutics
Apr 17, 2024
Maintains: Buy
Price Target: $20 → $30
Current: $12.93
Upside: +132.02%
Apr 16, 2024
Maintains: Buy
Price Target: $56 → $38
Current: $16.74
Upside: +127.00%
Mar 26, 2024
Upgrades: Buy
Price Target: $5
Current: $7.41
Upside: -32.52%
Mar 21, 2024
Initiates: Buy
Price Target: $62
Current: $31.53
Upside: +96.64%
Feb 9, 2024
Initiates: Buy
Price Target: $8
Current: $5.15
Upside: +55.34%
Dec 19, 2023
Initiates: Buy
Price Target: $27
Current: $42.25
Upside: -36.09%
Aug 23, 2023
Reiterates: Buy
Price Target: $70
Current: $23.18
Upside: +201.98%
Aug 31, 2022
Initiates: Buy
Price Target: $12
Current: $2.06
Upside: +482.52%
Jul 7, 2022
Maintains: Buy
Price Target: $16 → $8
Current: $3.97
Upside: +101.51%
Feb 9, 2022
Maintains: Buy
Price Target: $12,320 → $4,928
Current: $4.85
Upside: +101,508.25%